![Teva launches first DTC for Austedo into competitive tardive dyskinesia 2-drug market | Fierce Pharma Teva launches first DTC for Austedo into competitive tardive dyskinesia 2-drug market | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1622184941/CampaignImage.jpg?VersionId=gHnBXNNfFLK.Ce1UZv0iQmF7Ue01jwSd)
Teva launches first DTC for Austedo into competitive tardive dyskinesia 2-drug market | Fierce Pharma
![Metabolic pathways of tetrabenazine and deutetrabenazine. RR enantiomer... | Download Scientific Diagram Metabolic pathways of tetrabenazine and deutetrabenazine. RR enantiomer... | Download Scientific Diagram](https://www.researchgate.net/publication/339832458/figure/fig2/AS:867712867766272@1583890277427/Metabolic-pathways-of-tetrabenazine-and-deutetrabenazine-RR-enantiomer-depicted.png)
Metabolic pathways of tetrabenazine and deutetrabenazine. RR enantiomer... | Download Scientific Diagram
![Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers - Schneider - 2020 - Clinical and Translational Science - Wiley Online Library Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers - Schneider - 2020 - Clinical and Translational Science - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/bf1366db-64ba-4e30-b6d2-d7b8feb55498/cts12754-fig-0001-m.jpg)
Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers - Schneider - 2020 - Clinical and Translational Science - Wiley Online Library
![Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease - Chemdiv Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease - Chemdiv](https://www.chemdiv.com/wp-content/uploads/2015/11/deutetrabenazine.png)
Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease - Chemdiv
Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington Disease - Chemdiv
![Teva announces FDA approval of Austedo tablets for chorea associated with huntington's disease - Pharma Advancement Teva announces FDA approval of Austedo tablets for chorea associated with huntington's disease - Pharma Advancement](https://www.pharmaadvancement.com/wp-content/uploads/2017/04/teva_pharma.jpg)
Teva announces FDA approval of Austedo tablets for chorea associated with huntington's disease - Pharma Advancement
![Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® ( deutetrabenazine) tablets Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® ( deutetrabenazine) tablets](https://mma.prnewswire.com/media/1510758/Teva_Logo.jpg)
Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® ( deutetrabenazine) tablets
![Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association ... Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association ...](https://www.ehtrend.com.br/en/img/US_lnk_vpX5YQEwAABGRM_en.jpg)
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association ...
![Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US](https://pharmashots.com/public/images/20211116003948_ogImage_41.jpg)